Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02030483 · ClinicalTrials.gov registry record · Phase 1
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02030483 is a Phase 1 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 9 participants.
The verdict
NCT02030483, a Phase 1 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Our hypothesis is that treating relapsed or refractory multiple myeloma with PD 0332991 (Palbociclib) in combination with lenalidomide will result will be both effectively inducing myeloma plasma cell death as well maintaining a favorable side effect profile.
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Palbociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02030483
The ClinicalTrials.gov registry entry for NCT02030483 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02030483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02030483 about?
NCT02030483 is a clinical study titled "Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma". Our hypothesis is that treating relapsed or refractory multiple myeloma with PD 0332991 (Palbociclib) in combination with lenalidomide will result will be both effectively inducing myeloma plasma cell death as well maintaining a favorable side effect profile.
What is the current status of trial NCT02030483?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2014-02. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02030483?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT02030483?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.